C12Y304/15001

Use of angiotensin II (AII) receptor agonists to prevent or reduce hemodialysis-associated skeletal muscle cramps
09919022 · 2018-03-20 ·

Disclosed herein is a therapeutic intervention to prevent, reduce, or treat hemodialysis-associated skeletal muscle cramps by administering All receptor agonists or other pharmacologic agents that augment homeostatic responses to hemodialysis while preventing derecruitment of skeletal muscle capillaries.

Crystals of angiotensin-converting enzyme (ACE)
09670473 · 2017-06-06 · ·

The present invention relates to a crystal. In particular the present invention relates to a crystal of the N-domain of ACE protein. The present invention also relates to methods, processes, domain specific modulators, pharmaceutical compositions and uses of the N-domain crystal and the structure co-ordinates thereof.

ENZYME TREATMENT OF FOODSTUFFS FOR CELIAC SPRUE
20170119860 · 2017-05-04 ·

Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.

Oligonucleotide—containing pharmacological compositions and their use

The present invention relates to methods and compositions containing oligonucleotides suitable for administration to humans and other mammals.

MULTIVALENT DISPLAY ON ENVELOPED PARTICLES WITH HUMAN OLIGOMERIZATION DOMAINS
20250288662 · 2025-09-18 ·

Disclosed herein are recombinant fusion protein comprising transmembrane domains, display polypeptides, and human oligomerization domains, and enveloped particles containing the same, and methods of use.

Modified <i>Trichoderma </i>fungal strain for the production of an enzyme cocktail

The present invention relates to a novel strain of Trichoderma comprising genetic modifications that enable the improved production of an enzyme cocktail, involving at least upregulation of the transcription factor Xyr1 according to SEQ ID No. 1; disruption of the gene ACE1 according to SEQ ID No. 2; disruption of the gene SLP1 according to SEQ ID No. 3; and expression of the gene Cel3a from Rasamsonia emersonii according to SEQ ID No. 4.